EMA400

INHIBITORS

Product Details

CAT No.# CS-O-16982
Category Inhibitors
CAS 152362-51-1
Molecular Weight 507.59
Molecular Formula C32H29NO5
Purity: >98
Solubility: Soluble in DMSO
Appearance: Solid powder
Synonyms: EMA400; EMA 400; EMA-400; PD-126055; PD126055; PD 126055; 5-Benzyloxy-2-diphenylacetyl-6-methoxy-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid
References: Rice AS, Smith MT. Angiotensin II type 2-receptor: new clinically validated target in the treatment of neuropathic pain. Clin Pharmacol Ther. 2015 Feb;97(2):128-30. doi: 10.1002/cpt.29. Epub 2014 Dec 20. PubMed PMID: 25670516. McCarthy T. Development of EMA401 as an orally-administered, highly-selective angiotensin II type 2 receptor antagonist for the treatment of neuropathic pain. J Peripher Nerv Syst. 2014 Oct;19 Suppl 2:S13-4. doi: 10.1111/jns.12080_4. Review. PubMed PMID: 25269730.
Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
COA / MSDS:    View COA    MSDS    Enquire
The balance used are calibrated with weights traceable to National Standards NIST for accuracy
PEOPLE ALSO SEARCHED FOR: 1. MTX-211
2. Tropifexor
3. Cilofexor
4. PF-05089771
5. Ivosidenib
6. 1-(2-(2-chloro-3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethyl)-4-methylpiperazine
7. (1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl)
8. (E)-methyl 3-(3,5-difluoro-4-formylphenyl)acrylate
9. Rifabutin D6
10. Clindamycin Phosphate Sulfone trans-N-Oxide
11. loperamide D6 N oxide
12. Alpha-pyrrolidinovalerophenone
13. 11-Keto Loteprednol Etabonate
14. Dimenhydrinate Impurity D
15. 4-(Trifluoromethyl)phenyl propanol-1
16. 2-(Trifluoromethyl)phenyl propanol-1
17. bis(dimethylamino)boron chloride
18. Meclizine D8
19. 2-(2-aminothiazol-4-yl)-N-[2-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl) phenyl]acetamide
20. Glycopyrronium Bromide EP Impurity I




This page contains information about EMA400 Cas 152362-51-1 and its Inhibitors.
"Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk."